Since November 2016, Dillaha has been the chief executive officer and board member of CavtheRx, a pre-IND stage, virtual company. From April 2014 through January 2017, he was the chief operating officer and chief medical officer of New Haven Pharmaceuticals. He has also held positions at Insys Therapeutics (INSY), Sciele Pharma, and Sanofi-Synthelabo/Sanofi. The company’s 8-K filing with the U.S. Securities and Exchange Commission (SEC) indicate Dillaha will be paid $30,000 in cash per month for a minimum of six months, as well as reimbursed for expenses. He also has the option to buy 50,000 shares of the company stock once the FDA and the company agree on a protocol for Phase III trials for Proellex (telapristone acetate) for uterine fibroids.
Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the FDA has granted an “end of Phase 2” meeting to discuss the Phase 3 requirements to demonstrate both efficacy and safety for the development of Proellex® (telapristone acetate) for the treatment of uterine fibroids. The meeting is scheduled to occur before the end of April 2017.
Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has requested a meeting to discuss Phase 3 requirements for the development of Proellex® (telapristone acetate) for the treatment of endometriosis. The Company anticipates a meeting will be scheduled during the first half of 2017.
Repros Therapeutics Inc will abandon efforts to seek approval for its testosterone drug in the United States if an ongoing study fails, and shift focus to its uterine fibroids drug that showed promise in a mid-stage trial.